Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I) | MicrobiomeTrials← Back to trialsNCT07388550
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-06-14Est. Completion: 2028-01-01
Enrollment target: 15 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Post-COVIDPOST-Covid 19Post-COVID Conditions
Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are comm…
Amsterdam-Zuidoost, NetherlandsEst. completion Dec 31, 2027
COVID-19
Type I interferon (IFN-I) production is triggered by the detection of viral molecules, such as strands of viral RNA or D…
Lyon, FranceEst. completion Jun 2027